Screening the Screeners
This article was originally published in Start Up
Executive SummaryA host of start-ups want to make high-volume screening the method of choice for finding drug leads and for discovering the uses for those new, mysterious targets pouring out of the genetic databases, But few of the new firms are basing their long-term plans on screening services; most are either using their systems to look for their own drugs or still evolving their business plans along with their technologies.
You may also be interested in...
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?
Merck and UnitedHealth's Optum group have partnered to explore various value constructs.
Although stakeholders are interested in value-based models that link a drug’s performance to emerging evidence of improved patient outcomes, such agreements are difficult to implement and too limited in scope to drive a shift to value-based reimbursement. The authors suggest a new, structured approach to bring these contracts into the mainstream, thus transforming product reimbursement and fueling the shift from volume to value.